Table 3.
Relative Hazards of Arterial Thromboembolism During Discrete Time Periods, Stratified by Cancer Type and Thromboembolism Type
| Time Periods After Cancer Diagnosis* | |||||
|---|---|---|---|---|---|
| 0–1 Months | 1–3 Months | 3–6 Months | 6–9 Months | 9–12 Months | |
| Arterial thromboembolism | |||||
| All cancer | 5.2 (4.9–5.6) | 2.1 (2.0–2.2) | 1.4 (1.3–1.5) | 1.1 (1.1–1.2) | 1.1 (1.0–1.1) |
| Breast | 2.3 (2.0–2.7) | 1.3 (1.1–1.4) | 1.1 (1.0–1.2) | 0.9 (0.8–1.0) | 0.9 (0.8–1.0) |
| Lung | 9.6 (8.4–10.9) | 3.6 (3.2–4.0) | 2.3 (2.1–2.6) | 1.9 (1.7–2.1) | 2.2 (1.9–2.5) |
| Prostate | 1.7 (1.5–2.0) | 1.1 (1.0–1.3) | 1.0 (0.9–1.1) | 0.9 (0.8–1.0) | 0.8 (0.7–0.9) |
| Colorectal | 6.7 (5.7–7.8) | 2.1 (1.9–2.4) | 1.3 (1.2–1.5) | 1.0 (0.9–1.2) | 1.0 (0.9–1.1) |
| Bladder | 4.6 (3.5–6.0) | 2.2 (1.8–2.7) | 1.4 (1.1–1.6) | 1.4 (1.1–1.7) | 1.1 (0.9–1.3) |
| NHL | 6.1 (4.6–8.1) | 2.3 (1.8–2.9) | 1.8 (1.5–2.1) | 1.3 (1.0–1.6) | 1.2 (1.0–1.6) |
| Pancreas | 6.8 (5.1–9.2) | 3.0 (2.3–3.7) | 1.7 (1.4–2.2) | – | – |
| Gastric | 6.0 (4.1–8.9) | 3.0 (2.2–4.3) | 2.4 (1.7–3.2) | 1.1 (0.7–1.5) | 1.1 (0.8–1.6) |
| Myocardial infarction | |||||
| All cancer | 7.3 (6.5–8.2) | 3.0 (2.7–3.3) | 1.8 (1.6–1.9) | 1.3 (1.2–1.4) | 1.0 (1.0–1.1) |
| Breast | 3.8 (2.8–5.0) | 1.8 (1.4–2.2) | 1.6 (1.3–1.9) | 1.0 (0.8–1.2) | 0.7 (0.5–0.8) |
| Lung | 10.1 (8.0–12.8) | 4.8 (4.0–5.8) | 2.8 (2.4–3.3) | 2.4 (2.0–2.8) | 2.5 (2.1–3.0) |
| Prostate | 1.9 (1.5–2.6) | 1.7 (1.4–2.1) | 1.2 (1.0–1.4) | 0.9 (0.8–1.1) | 0.7 (0.6–0.9) |
| Colorectal | 12.6 (9.5–16.7) | 3.3 (2.7–4.1) | 1.8 (1.4–2.2) | 1.2 (0.9–1.5) | 1.0 (0.8–1.3) |
| Bladder | 5.6 (3.6–8.6) | 2.6 (1.9–3.6) | 1.5 (1.1–1.9) | 1.8 (1.3–2.4) | 1.2 (0.9–1.7) |
| NHL | 9.1 (5.4–15.6) | 3.3 (2.2–4.9) | 2.1 (1.5–2.8) | 1.4 (1.0–2.0) | 1.0 (0.7–1.5) |
| Pancreas | 13.9 (7.7–25.0) | 4.0 (2.6–6.1) | 2.1 (1.4–3.0) | – | – |
| Gastric | 11.0 (5.3–22.6) | 8.0 (4.0–16.0) | 3.3 (1.9–5.5) | 1.0 (0.5–1.8) | 1.0 (0.5–2.0) |
| Ischemic stroke | |||||
| All cancer | 4.5 (4.1–4.8) | 1.7 (1.6–1.8) | 1.3 (1.2–1.3) | 1.0 (1.0–1.1) | 1.1 (1.0–1.2) |
| Breast | 1.8 (1.5–2.2) | 1.1 (1.0–1.3) | 0.9 (0.8–1.0) | 0.9 (0.8–1.0) | 1.0 (0.9–1.1) |
| Lung | 9.3 (8.0–10.9) | 3.1 (2.7–3.5) | 2.1 (1.9–2.4) | 1.7 (1.5–2.0) | 2.0 (1.8–2.4) |
| Prostate | 1.6 (1.3–2.0) | 0.9 (0.8–1.1) | 0.9 (0.8–1.0) | 0.9 (0.8–1.0) | 0.9 (0.8–1.0) |
| Colorectal | 4.6 (3.9–5.6) | 1.7 (1.5–2.0) | 1.2 (1.1–1.4) | 1.0 (0.8–1.1) | 1.0 (0.8–1.1) |
| Bladder | 4.1 (2.9–5.8) | 2.0 (1.5–2.5) | 1.3 (1.1–1.7) | 1.2 (0.9–1.5) | 1.1 (0.8–1.4) |
| NHL | 4.7 (3.4–6.6) | 1.9 (1.5–2.5) | 1.5 (1.2–1.9) | 1.2 (0.9–1.5) | 1.3 (1.0–1.7) |
| Pancreas | 5.0 (3.6–6.9) | 2.6 (2.0–3.4) | 1.6 (1.2–2.1) | – | – |
| Gastric | 4.5 (2.9–7.1) | 1.9 (1.3–2.9) | 1.9 (1.3–2.8) | 1.2 (0.8–1.7) | 1.1 (0.7–1.8) |
Relative hazards are reported as n (95% confidence interval).
*
Data are shown through the median period of follow-up for each cancer type up to a maximum of 1 year.
NHL indicates non-Hodgkin lymphoma.